Board of Directors
Dr. Kakkis is best known for his work over the last 18 years to develop novel treatments for rare disorders. He began his work developing an enzyme replacement therapy (Aldurazyme®) for the rare disorder MPS I, with minimal funding and support. The struggle to get the therapy translated from a successful canine model to patients succeeded due to the critical financial support of the Ryan Foundation, a patient organization formed by Mark and Jeanne Dant for their son Ryan. See Full Bio
Eran Nadav, Ph.D. – Managing Director, TPG Biotech
Chairman of the Board
Dr. Nadav is a Managing Director at TPG Biotech®, the life science venture investment arm of TPG (formerly known as Texas Pacific Group), a global private investment firm. Dr. Nadav joined TPG Biotech in 2007 with the focus on global pharmaceuticals and biotechnology investments. Prior to this, Dr. Nadav served as Business Development Director at Eisai Pharmaceuticals in New Jersey for four years, where he evaluated and negotiated notable licensing and acquisition deals. Prior to this, Dr. Nadav worked for the Israeli office of JJDC, the venture capital subsidiary of Johnson & Johnson, where he analyzed and executed investments in innovative technologies, medical devices and biopharmaceuticals. Previously, he was with Neurim Pharmaceuticals, supporting the clinical development of Circadin®. Before his professional career and academic studies, Dr. Nadav served in the Israel Defense Forces for three years. Dr. Nadav holds a B.S. magna cum laude, M.S. magna cum laude and Ph.D. in biochemistry, as well as an MBA from Tel Aviv University.
– Partner, Fidelity Biosciences
Ben Auspitz has worked in pharmaceuticals and life-science for over fifteen years, both in industry and as a consultant. Most recently before joining Fidelity, he served as Therapeutic Area Head for Immuno-Inflammatory products at CombinatoRx Inc. during its growth from an angel-backed start-up to a publicly-listed company (NASDAQ: CRXX). In this role, he oversaw the advancement of seven programs from assay stage into phase II human clinical studies, and was co-inventor on 15 product patents. He also served as Director for Corporate Strategy at CombinatoRx, where he was responsible for product in-licensing, new business development, and the build-out and $20M financing of an infectious disease subsidiary. His consulting experience has included work in clinical development, product launch, M&A, and medical marketing. Sample projects include sales force optimization and managed markets strategy for Celebrex, the first-in-class COX-2 inhibitor, and clinical development strategy for gene-therapy, protein, and small molecule products.
He holds a B.A. from Harvard University.
Mr. Auspitz serves on the Board of Directors of Ligocyte Pharmaceuticals, BIKAM Pharmaceuticals, and Ultragenyx Pharmaceutical.
Marten Steen, M.D., Ph.D. – Partner, HealthCap
Dr. Steen worked previously with global business development at Merck Serono, focusing on both product and technology licensing. Prior to Merck Serono, he was a medical associate with HealthCap. Dr. Steen is a Medical Doctor trained at Lund University. He has pursued research in the field of protein chemistry and coagulation at Lund University and Novo Nordisk, rendering him a PhD in Clinical Chemistry in 2003. He is the author of 16 scientific papers and published in peer-reviewed journals. He has also a B.Sc. degree in Business Administration from the Lund University School of Economics and Management.
William Aliski – Biotechnology Executive
Mr. Aliski joined Ultragenyx as a Board member in January of 2011. He is an experienced orphan disease and biotech executive, having worked on the commercialization of a number of orphan products in the US as well as international markets. His commercial experience includes Chief Commercial Officer for Foldrx, an early stage company purchased by Pfizer, General Manager for Biomarin Europe and executive level positions at TKT 5S/Shire and Genzyme Corp. In addition he has developed pricing and reimbursement models and patient support programs for a number of enzyme replacement therapies including Ceredase/Cerezyme for Gaucher Disease and Replagal for Fabry Disease. Mr Aliski is currently a commercial consultant for early stage orphan disease companies and also serves on the board of Edimer Pharmaceuticals.
He earned an undergraduate degree in economics from Boston College and a MPA from the Kennedy School of Government at Harvard University.
Linsley, MBA – Managing Partner, Pappas
Mr. Linsley joined Ultragenyx as a Board observer in March 2012. He is an experienced operating executive and venture capital investor who prior to joining Pappas Ventures in 2000 served as Chief Financial Officer of TriPath Imaging, Inc., a medical device company that was acquired in 2006 by Becton Dickinson. Mr. Linsley played a key role in the three-way merger between AutoCyte, NeoPath and Neuromedical Systems that created TriPath. Prior to the formation of TriPath, he served as Chief Financial Officer and Vice President of Operations at AutoCyte where he led the company in a successful public equity offering in 1997. From 1991 to 1997, Mr. Linsley worked as an investment professional with Ampersand Ventures, a leading venture capital firm based in Boston. He previously served as a management consultant with Bain & Co. and McKinsey & Co., and was a certified public accountant with Arthur Andersen LLP.
Mr. Linsley also currently serves as a
director of BaroSense and Milestone
Pharmaceuticals, and an observer at
LipoScience, Balance Therapeutics and Liquidia
Technologies. He received a B.A. in
Economics from Trinity College, a M.S. in
Accounting from New York University, and a
M.B.A. from the Wharton School at the
University of Pennsylvania.
Geoff Duyk, M.D., Ph.D. – Partner and Managing Director, TPG Biotech
Prior to joining TPG in 2004, Dr. Duyk served on the Board of Directors and was President of Research & Development at Exelixis, where he led a 550+ person group focused on the discovery and development of small molecule therapeutics. Prior to Exelixis, he was one of the founding scientific staff at Millennium Pharmaceuticals. As Vice President of Genomics at Millennium, Geoff was responsible for building and leading the informatics, automation, DNA sequencing and genotyping groups as well as the mouse and human genetics group.
Prior to his tenure at Millennium, Dr. Duyk was an Assistant Professor at Harvard Medical School (HMS) in the Department of Genetics and Assistant Investigator of the Howard Hughes Medical Institute (HHMI). While at HMS, Dr. Duyk was a Co-Principal Investigator in the National Institutes of Health (NIH) funded Cooperative Human Linkage Center. Dr. Duyk has been and continues to be a member of numerous NIH panels and oversight committees focused on the planning and execution of the Human Genome Project.
Dr. Duyk graduated from Wesleyan University (1980) with a BA in Biology and was elected to Phi Beta Kappa. He holds a Ph.D. and M.D. from Case Western Reserve University and completed his medical and fellowship training at University of California, San Francisco. While at UCSF, Dr. Duyk was a fellow of the Lucille P. Markey Foundation and was also awarded a post-doctoral fellowship from the Howard Hughes Medical Institute.
John Klock, M.D. – Biotechnology Entrepreneur
Dr. Klock received his medical degree at Tulane University, his medical training at the University of California San Francisco and Massachusetts General Hospital. He is a board-certified Internist and Hematologist-Oncologist and practiced medicine and did research at the University of California San Francisco from 1970-1982. Since 1982 he has been involved in the start-up of five medical companies. In these companies he has worked alongside of many talented people to develop and bring to market: 1) a novel cancer treatment, 2) the first rapid AIDS test, 3) a comprehensive test for detecting metabolic diseases of children and 4) several drugs for treating genetic diseases of children as a founder for BioMarin. He continues to be involved in introducing novel concepts into medical practice and is on the board of several medical companies. Dr Klock has over 70 peer-reviewed medical and scientific publications and 8 granted US Patents. Presently, in collaboration with several private preventive medical clinics, he is applying modern medical technologies for disease prediction and health screening.